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a b s t r a c t
Vaccination is the most effective way to prevent and control infection by inﬂuenza viruses, and a cell-
culture-based vaccine production system is preferred as the future choice for the large-scale production
of inﬂuenza vaccines. As one of the WHO-recommended cell lines for producing inﬂuenza vaccines, Vero
cells do not efﬁciently support the growth of the current inﬂuenza A virus vaccine donor strain, the
A/Puerto Rico/8/1934 (PR8) virus. In this study, a single mutation of K86R in the NS2 protein can
sufﬁciently render the high-yielding property to the PR8 virus in Vero cells. Further analysis showed that
the later steps in the virus replication cycle were accelerated by NS2K86R mutation, which may relate to
an enhanced interaction between NS2K86R and the components of host factor F1Fo-ATPase, FoB and F1β.
Because the NS2K86R mutation does not increase PR8 virulence in either mice or embryonated eggs, the
PR8-NS2K86R virus could serve as a promising vaccine donor strain in Vero cells.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza A viral infection is one of the most devastating
infectious diseases in human history. In the past century, there
were four inﬂuenza pandemics that caused threats around the
world (Yoon et al., 2014). Annually, seasonal inﬂuenza viruses
infect at least 10–20% of people, and the high-risk populations are
recommended to receive vaccines (Belsey et al., 2006). Vaccination
is the most efﬁcient way to prevent inﬂuenza infection. However,
due to antigenic drift and shift, inﬂuenza vaccines should be
updated annually to best protect against the circulating strains,
and scaled-up production is also required, especially during
pandemics (Lu et al., 2006). Currently, the production of inﬂuenza
vaccines is primarily based on an egg-based production system.
Although the system has been used for decades, several inherent
drawbacks exist, such as labor intensity, lengthy timeline, limited
production capacity, antigenic changes and allergenic responses
(Kistner et al., 1998; Vepachedu et al., 2012; Wright, 2008).
Considering that one to two eggs are required to produce each
vaccine dose, millions of eggs are required to produce a given
inﬂuenza vaccine during the inﬂuenza season (Montomoli et al.,
2012).
Although egg-based vaccines should be prepared approxi-
mately 6 months in advance, vaccine production is often delayed
because pandemics cannot be predicted accurately (Ozaki et al.,
2004). In contrast to an egg-based production system, a cell-based
production system is easier to scale up, produces fewer changes in
antigenicity and causes no allergenic responses (Hatz et al., 2012;
Mochalova et al., 2003). Many cell lines have now been licensed
for vaccine production, including Vero cells from an African green
monkey kidney (Barrett et al., 2009; Kistner et al., 1998), MDCK
cells from a canine kidney (Genzel et al., 2006) and PER.C6 cells
from human retinoblasts (Montomoli et al., 2012; Pau et al., 2001).
Among them, only Vero cells have been used to produce multiple
human vaccines for decades, including the poliovirus and rabies
virus vaccines (Montagnon et al., 1981). The safety of human
vaccines derived from Vero cells has been proven, and their
production has been easily scaled up for use at the commercial
level. Furthermore, the inﬂuenza vaccines derived from Vero cells
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have been estimated to induce proportional humoral responses
and even higher cellular immune responses compared with those
derived from eggs (Bruhl et al., 2000).
When reverse genetic techniques for inﬂuenza A viruses were
recently applied to generate vaccine candidates, the advantages of
this technique became more apparent and were shown to not only
save time in generating vaccine seed viruses (Hoffmann et al.,
2002) but also improve the viral growth properties and attenua-
tion of the vaccine strain by introducing designed mutations (Lu
et al., 2006). Traditionally, the vaccine seed virus was derived by
co-infecting eggs with the circulating strain and the egg-adapted
vaccine donor virus PR8, followed by screening for progeny viruses
containing the hemagglutinin (HA) and neuraminidase (NA) genes
from the circulating strain and the remaining genes from PR8
(Ozaki et al., 2004; Wood and Robertson, 2004). When the cell-
based production system starts replacing the traditional reassort-
ment method, a problem arises because the vaccine donor virus
PR8 is not adapted to Vero cells and grows to a low titer in Vero
cells (Lau and Scholtissek, 1995). Although several strategies have
been developed to improve the growth of PR8 in Vero cells (Genzel
et al., 2010; Kaverin and Webster, 1995), the viral titer for PR8-
based vaccine strains in Vero cells is still not satisfactory, which
has led to a demand for further improvement.
In this study, we rescue a Vero-adapted PR8 virus by generating
reassortant viruses carrying viral gene segments from a Vero-
adapted WSN virus. By viral gene screening and mutagenesis, we
found that a single amino acid mutation, NS2K86R, is capable of
making PR8 grow efﬁciently in Vero cells. More infectious virus
particles can be released from PR8-NS2K86R-infected Vero cells
than from the wild-type PR8-infected cells. Our study suggests
that NS2K86R binds more efﬁciently to F1β and FoB, the compo-
nents of host factor F-type proton-translocating ATPase membrane
protein that facilitates virus budding. Thus, the modiﬁed PR8-
NS2K86R virus could be a promising vaccine donor virus for Vero-
cell-based vaccine production systems.
Results
A PR8 reassortant virus carrying the WSN NS segment grows
efﬁciently in Vero cells
To develop an efﬁcient vaccine donor strain for the Vero cell
culture system, reverse genetic technology and virological ana-
lyses have been employed. The wild-type (WT) vaccine donor
virus, PR8, grew slowly and formed tiny plaques in Vero cells at
48 h post-infection (Fig. 1A) (Kaverin and Webster, 1995). In
contrast, a laboratory-adapted strain, WSN, grew efﬁciently in
Vero cells by forming larger plaques at 48 h post-infection
(Fig. 1A). We therefore individually replaced PR8 virus genes with
WSN virus genes to promote the growth of PR8 in Vero cells.
Because mutations in the HA and NA surface proteins may alter
virus antigenicity, we only focused on internal viral genes. The PR8
gene segments were substituted by WSN gene segments in a PR8
background to rescue the following reassortant viruses using
reverse genetics: PR8–WSN M (where the M gene was from
WSN), PR8–WSN NS (where the NS gene was from WSN), and
PR8–WSN 4P (where the three polymerase genes and the NP gene
were from WSN) (Ozaki et al., 2004). Plaque formation by these
reassortant viruses was analyzed in Vero cells. The data in Fig. 1A
show that only the PR8–WSN NS virus can form larger plaques
than the WT PR8 virus and that the PR8–WSNM and PR8–WSN 4P
viruses showed no growth advantage over the WT PR8 virus. The
growth kinetics further conﬁrmed that the NS gene from WSN,
compared with other WSN genes, could signiﬁcantly promote the
growth of PR8 in Vero cells (Fig. 1B). The PR8–WSN NS virus grew
much faster than the original PR8 virus, with an approximately
128 and 55 times higher viral titers than that of PR8 at 24 h and
48 h post-infection respectively (the mean viral titers of PR8–WSN
NS and PR8 at 24 h post-infection are 3.7n105 and 2.9n103
respectively, about 128 fold, Po0.01; the mean viral titers of
PR8–WSN NS and PR8 at 48 h post-infection are 1.8n106 and
3.3n104 respectively, about 55 fold, Po0.05) (Fig. 1B). In contrast,
the PR8–WSN M and PR8–WSN 4P grew even slower and to a
lower viral titer than the PR8 virus. Therefore, we conclude that
the NS gene from the WSN virus is able to facilitate growth of the
PR8 virus in Vero cells.
Speciﬁc amino acids in the WSN NS gene promote the growth of PR8
in Vero cells
The NS gene of inﬂuenza A viruses directs the synthesis of two
mRNAs by alternative splicing, NS1 and NS2 (NEP) (Bullido et al.,
2001; Robb et al., 2009), as shown in Fig. 2A. An alignment of the
NS genes from WSN and PR8 shows 11 nucleotide differences,
resulting in seven amino acid mutations in the NS1 protein
(Fig. 2A, NS1 mRNA) and six amino acid mutations in the NS2
protein (Fig. 2A, NS2 mRNA). Among these amino acid mutations,
two mutations, F103S and M106I, are known to contribute to the
stabilization of NS1 binding with the host cleavage and polyadenyla-
tion speciﬁcity factor CPSF30 (Das et al., 2008), whereas the functions
of the other mutations have not previously been reported. To
determine the Vero-adaptive mutations in the NS gene, each of the
unique 11 WSN NS nucleotides were introduced into the PR8 NS gene,
and 10 reassortant viruses were generated (S103F and I106M were
introduced in combination because they function together).
The growth characteristics of the 10 reassortant viruses were
evaluated in Vero cells by analyzing growth curves and plaque
assays. As shown in Fig. 2B, the viruses harboring mutations at
NS1K55E, NS1D101H, NS1D189M/NS2M31I, NS2E63G and NS2K86R all
grew faster than the WT PR8 virus, although the degrees of
Fig. 1. Growth curves and plaque assays for the reassortant viruses between PR8
and WSN. (A) Plaque assays for reassortant viruses in Vero cells. Cellular mono-
layers cultured in a 24-well plate were infected with the indicated viruses and
incubated at 37 1C in 5% CO2. At 48 h post-infection, the monolayer was ﬁxed with
4% PFA, and immunostaining was performed using an anti-NP polyclonal antibody
conjugated with HRP, followed by True Blue substrate coloration. (B) Growth curves
for the reassortant viruses in Vero cells. Cellular monolayers were infected at an
MOI of 0.001 and incubated at 37 1C in 5% CO2. At 2, 24, 48, 72, and 96 h post-
infection, the supernatants were harvested, and viral titers were determined by
plaque assays in MDCK cells. The viral titers provided for each point are the mean
titers with standard deviations calculated from three independent experiments.
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Fig. 2. Growth curves and plaque assays for the PR8 viruses containing NS mutations. (A) Location of amino acids differences between PR8 and WSN. The NS gene alignment
fromWSN and PR8 shows 11 nucleotide differences across the NS gene segment, including seven amino acid mutations in the NS1 protein (NS1 mRNA) and six mutations in
NS2 (NS2 mRNA). (B) Growth curves in Vero cells for the PR8 viruses containing different mutations. Cellular monolayers were infected at an MOI of 0.001 and incubated at
37 1C in 5% CO2. At 24, 48, 72, and 96 h post-infection, the supernatants were harvested, and viral titers were determined by plaque assays in MDCK cells. The viral titers
provided for each point are the mean titers with standard deviations calculated from three independent experiments. All the data are expressed as the mean with SD.
(C) Viral titers of PR8 viruses containing different mutations in Vero cells at 48 h post-infection. All the data are expressed as the mean with SD. nnnPo0.001, nPo0.05.
(D) Plaque assays in Vero cells for the WT PR8, WSN, PR8–WSN NS and PR8-NS2K86R viruses containing different mutations. Cellular monolayers cultured in a 24-well plate
were infected with the indicated viruses and incubated at 37 1C in 5% CO2. At 48 h post-infection, the monolayer was ﬁxed with 4% PFA, and immunostaining was performed
using an anti-NP polyclonal antibody conjugated with HRP, followed by True Blue substrate coloration. The results shown are representative of three independent
experiments.
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enhanced growth were different (Fig. 2B). Among them, the virus
containing the NS2K86R mutation grew the fastest with an approxi-
mately 100 times higher viral titer than the PR8 virus at 48 h post-
infection (Fig. 2C). The results from the plaque assays showed a
similar pattern, with the NS2K86R mutant exhibiting a plaque
morphology similar to that of the WSN virus (Fig. 2D). Combining
all the functional amino acids—NS1K55E, NS1D101H, NS1D189M/
NS2M31I, NS2E63G and NS2K86R—in the PR8 NS gene did not further
elevate viral growth compared with the NS2K86R virus (data not
shown). Therefore, we speciﬁcally focused our mechanistic studies
on the high-growth capability of NS2K86R.
NS2K86R increases viral particle production without affecting either
the vRNP exporting process or viral replication and transcription
To elucidate the underlying mechanism of how NS2K86R pro-
motes viral growth in Vero cells, we examined several well-
characterized functions of NS2. First, the NS2 protein is well
known for exporting vRNPs from the nucleus (O’Neill et al.,
1998; Shimizu et al., 2011). To evaluate whether the NS2K86R
mutation affects the vRNP exportation process, Vero cells were
infected with either PR8-WT or PR8-NS2K86R viruses at an MOI of
1. The cells were then harvested at 4 h, 6 h, and 8 h post-infection,
followed by cell fractionation to separate the nuclear and cyto-
plasmic fractions. The data in Fig. 3A show that there were no
signiﬁcant differences in the cytoplasmic and nuclear distributions
of the NP protein in cells infected with either virus. Second, the
NS2 protein from a human-adapted virus was reported to increase
polymerase activity of an avian virus in mammalian cells (Manz
et al., 2012). To test if NS2K86R affects the viral polymerase activity,
a mini-replicon assay was performed in Vero cells transfected with
plasmids expressing NP, PB1, PB2, and PA, together with pPolI-HA-
luc (a luciferase reporter gene mimicking vRNA) and pRL-SV40 (a
transfection control) in the presence of WT NS2 or NS2K86R. As
observed in other studies (Gorai et al., 2012; Manz et al., 2012;
Robb et al., 2009), we also observe that NS2 could slightly increase
the polymerase activity at a low expression level (Fig. 3B, when
20 ng of NS2 was compared to 20 ng of vector), while it inhibited
the polymerase activity at a high plasmid concentration (Fig. 3B,
when 100 ng, 300 ng, 500 ng of NS2 was compared to vector at the
respective plasmid concentrations). Nevertheless, no difference
was observed between NS2 and NS2K86R in their contribution to
polymerase activity at different plasmid concentrations (Fig. 3B).
We further tested the polymerase activity of PR8-WT and PR8-
NS2K86R viruses during infection. For this, Vero cells were trans-
fected with the pPolI-HA-Luc and pRL-SV40 plasmids 24 h before
infection with the viruses at an MOI of 5. The polymerase activities
of the two viruses were comparable at 4 h and 8 h post-infection.
The results were in agreement with the mini-replicon assay and
showed that the NS2K86R mutation minimally affects the polymer-
ase activity (Fig. 3C).
To conﬁrm that the transcription and replication of viral
genomes, which relies on polymerase activity, are also comparable
between the PR8-NS2K86R and PR8-WT viruses, we tested the
vRNA, mRNA and cRNA levels in Vero cells infected with each
virus. For this analysis, Vero cells were infected with PR8-WT or
PR8-NS2K86R, each at an MOI of 1. Total RNA was extracted from
the cells at the indicated times post-infection, and the copies of
vRNA, mRNA and cRNA were quantiﬁed by primer-speciﬁc RT-PCR
(Kawakami et al., 2011). The data in Fig. 3D show that there were
no signiﬁcant differences in the copies of vRNA, mRNA and cRNA
between the PR8-WT and PR8-NS2K86R viruses.
The data in all suggest that NS2K86R promotes the production of
viral particles without affecting the early steps till the transcrip-
tion and replication of the viral genome.
The NS2K86R mutation promotes late steps in the viral replication
cycle
Because neither the viral transcription/replication nor poly-
merase activity was affected by NS2K86R, we hypothesized that
NS2K86R may promote later steps in the viral replication cycle, such
as the viral assembly and budding processes. For this, a single
replication cycle was analyzed by collecting cell lysis and super-
natants from high-MOI-infected cell within 12 h post-infection. As
expected, the viral titer of PR8-NS2K86R-infected cells showed
signiﬁcant higher titer than that of PR8-WT-infected cells in late
infection hours starting at 8 h post-infection (the mean viral titer
of PR8-WT and PR8-NS2K86R was 3.1n104 and 2.9n105 at 8 h post-
infection respectively, Po0.001) (Fig. 4A). When we further
examined the intracellular and extracellular viral protein levels,
the data in Fig. 4B and C show that the M1 and NP levels in the cell
lysates were almost equal between PR8-WT- and PR8-NS2K86R-
infected cells. In contrast, the M1 and NP levels in the culture
supernatants from PR8-NS2K86R-infected cells were signiﬁcantly
higher than those from PR8-WT-infected cells at 12 h post-infection
(Fig. 4B and C). We therefore assumed that the NS2K86R mutation
affected later steps in the viral replication cycle after viral translation.
The NS2 protein was previously reported to be involved in
regulating virion formation and/or budding via association with
components of the F-type proton-translocating ATPase membrane
protein complex (F1Fo-ATPase). NS2 was detected to bind F1Fo-
ATPase subunit F1β mediated by another membrane spanning
subunit FoB (Gorai et al., 2012). We then tested whether there is
an interaction among NS2, F1β and FoB, and whether this inter-
action is promoted by the NS2K86R mutation. To address this
question, HA-tagged NS2-WT or HA-tagged NS2K86R was trans-
fected into Vero cells for 48 h before the cells were collected and
immunoprecipitated with anti-HA antibodies. The data in Fig. 4D
show that larger amounts of endogenous F1β and FoB were co-
precipitated with NS2K86R than with NS2-WT, indicating that the
complex interaction among NS2, FoB and F1βwas enhanced by the
NS2K86R mutation, which may in turn contribute to the high
growth of the PR8-NS2K86R virus in Vero cells.
NS2K86R does not affect the antigenicity and pathogenicity of the PR8
virus
To serve as a vaccine seed, a virus must retain its antigenic
properties during the vaccine production procedures (Ozaki et al.,
2004). To determine whether antigenic changes occurred in the
PR8-NS2K86R virus, HI assays were applied to compare the anti-
genicity of the PR8-NS2K86R virus with the WT PR8 virus using
antiserum from mice infected with PR8. The antigenicity of PR8-
NS2K86R viruses was indistinguishable from that of WT PR8
(Table 1). To further test the genetic stability, PR8-NS2K86R viruses
were blindly passaged in Vero cells 3 times, resulting in a virus
named PR8-NS2K86R-3. No additional mutations occurred in the
genome of PR8-NS2K86R-3, suggesting that the fast growth prop-
erty of NS2K86R could be passed stably to progeny viruses.
To test whether the NS2K86R mutation could enhance viral patho-
genicity, virulence was tested in chicken embryos and a mouse model
(Table 1). The 50% embryo lethal dose (ELD50) and the 50% mouse
lethal dose (MLD50) of the WT PR8 and PR8-NS2K86R viruses were
similar to each other. This ﬁnding demonstrates that the NS2K86R
mutation does not enhance the viral virulence in eggs or mice.
Discussion
Although several antiviral drugs have been approved against inﬂu-
enza virus infections, such as M2 ion channel blockers (amantadine and
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Fig. 3. The NS2K86R mutation does not affect the polymerase activity or vRNP export from the nucleus. (A) The vRNP export process was detected by cell fraction. Vero cells
infected with viruses were collected at the indicated times post-infection, and the cytoplasmic and nuclear fractions were extracted. The viral NP protein, GAPDH and
histones were detected by western blotting. (B) The polymerase activity of viruses was tested by a mini-replicon assay. One hundred nanograms each of PB1, PB2, PA, and NP
in pHW2000; 100 ng of human pPolI-HA-luc; and 10 ng of pRL-SV40 (Promega) were co-transfected into Vero cells, which were harvested 24 h post-transfection. Different
concentrations of NS2-expressing plasmids, of 20 ng, 50 ng, 100 ng, 300 ng and 500 ng, were co-transfected into Vero cells. The expressions of NP and NS2 in the cell lysis
were detected by anti-NP antibodies and anti-HA tag antibodies respectively. All the data are expressed as the mean with SD. NS, not signiﬁcant in statistical analysis.
(C) Polymerase activity during viral infection. Vero cells transfected with 100 ng of human pPolI-HA-luc and 10 ng of pRL-SV40 (Promega) were cultured for 24 h before viral
infection. Supernatants were harvested at 24 h post-infection, and the data were normalized to the activity of the PR8 sample. The expressions of NS1 and NP in cell lysis
were detected by anti-NP antibodies and anti-NS1 antibodies respectively. All the data are expressed as the mean with SD. NS, not signiﬁcant in statistical analysis.
(D) Quantitation of viral RNA levels for PR8 and PR8-NS2K86R during infection. Vero cells infected with viruses were harvested at the indicated times post-infection, and the
total RNA was isolated and subjected to quantitative RT-PCR for segment 5 transcripts (NP genes). All the data are expressed as the mean with SD. Differences in relative RNA
levels less than two fold were considered not signiﬁcant, and there was no signiﬁcant differences in vRNA, cRNA and mRNA levels between PR8-WT and PR8-NS2K86R
infections.
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rimantadine) and neuraminidase (NA) inhibitors (oseltamivir and
zanamivir) (Johansson and Cox, 2011; Leyssen et al., 2008), drug-
resistant variants have been isolated from patients (Seibert et al.,
2012; Suzuki et al., 2011). Faced with frequent epidemics and sporadic
pandemics caused by inﬂuenza viruses, vaccination remains the most
efﬁcient way to prevent inﬂuenza virus infections. Recently, cell-based
vaccine production systems are recognized as having advantages over
the classical egg-based production system. Vero cells are an approved
cell line that has been used for human vaccine production for decades
and is recommended for inﬂuenza vaccine production by the WHO
(Genzel and Reichl, 2009). However, Vero cells cannot support the
growth of inﬂuenza viruses efﬁciently, and the yield of inﬂuenza viruses
from Vero cells is low. In this study, we generated a Vero-adaptive PR8
virus by introducing a single mutation into the PR8 NS2 protein. The
growth of the modiﬁed PR8 virus (PR8-NS2K86R) is enhanced approxi-
mately 100 times compared with WT PR8 in Vero cells due to a more
efﬁcient production of infectious viral particles.
To produce inﬂuenza vaccines in cell culture, all producers face
the common problem of how to improve the titer of inﬂuenza
vaccine seed viruses (Feng et al., 2011). Many strategies have been
applied for the development of efﬁcient, robust, scalable cell-
based inﬂuenza vaccine production systems, including experimen-
tation with the culture conditions, cellular metabolism and the
bioreactor model (Hornickova, 1997; Kaverin and Webster, 1995;
Mohler et al., 2005). Efforts have also been made to modify the
vaccine strain genetically to improve viral growth and vaccine
production. For example, a high-yielding reassortant inﬂuenza A
vaccine donor virus was obtained by introducing a mutation at
an HLA-A 2.1-restricted CD8þ CTL epitope on the NS1 protein
(Terajima et al., 1999). A single amino acid change of either G186V
Fig. 4. The NS2K86R mutation promotes viral release by enhancing the interaction between NS2 and host factor F1β. (A) Single-step growth curves. The supernatants of Vero
cells infected with viruses at a high MOI of 1 were harvested, and viral titration was performed in MDCK cells. All the data are expressed as the mean with SD. nnPo0.01,
nnnPo0.001. (B) Detection of released viral particles. Vero cells were infected with viruses at an MOI of 5, and the cell lysates (cell) and supernatants were harvested at the
indicated post-infection times for western blotting. Actin and the viral proteins M1 and NP were detected. (C) The Release Efﬁciency of viral particles obtained from the
experiment described in B was calculated as follows: Release Efﬁciency¼amount of M1 in supernatants/(amount of M1 in cell lysates/amount of actin in cell lysates). The
amount of M1 in released virions and the amount of actin were acquired by analyzing the respective Western Blot images in B with software Image J. All the data are
expressed as the mean with SD. **Po0.01. (D) Co-immunoprecipitation of endogenous F1β and FoB with NS2. Proteins from NS2-expressing cells were immunoprecipitated
using an anti-HA antibody and were blotted for HA (to detect HA-tagged NS2), F1β and FoB.
Table 1
PR8 and PR8-NS2K86R viral antigenicity was tested by HI assay, and viral patho-
genicity was tested in eggs (ELD50) and mice (MLD50).
Virus HI titer ELD50 #(log
PFU)
MLD50 #(log
PFU)
Negative
serum
PR8
serum
PR8 o1:10 1:320 5.25 2.50
PR8- NS2K86Ro1:10 1:320 5.33
2.67
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or A196T in the HA resulted in high growth of the A/Singapore/21/
04 strain in eggs (Lu et al., 2006). Four mutations in the PR8
backbone contributed to the high growth of PR8 in Vero cells after
20 passages (Hu et al., 2015). And one high-growth strain was
generated after serial passages and plaque puriﬁcation of
H5N1vaccine strain (Tseng et al., 2011). Here, we intend to obtain
a Vero-adapted PR8 virus by combination with a well-adapted
stain WSN virus. Comparing the growth kinetics of the WSN virus,
the PR8 virus and PR8 reassortants carrying internal viral genes
from WSN, we found that the WSN virus is much better adapted
than the PR8 virus for growth in Vero cells and that the NS
segment from WSN can promote efﬁcient growth of PR8 in Vero
cells. The growth advantage of the NS segment from WSN was
conveyed with a single amino acid mutation, NS2K86R.
The NS2 protein plays an important role during the viral
replication cycle. It can affect viral genome transcription/replica-
tion, is involved in viral polymerase exportation from the nucleus.
Recently NS2 was reported to facilitate virion formation/budding.
Co-immunoprecipitation and mass spectrometry were used to
demonstrate that NS2 interacts with host factor F1β and FoB,
subunits of the F1Fo-ATPase found in mitochondria and at the plasma
membrane (Gorai et al., 2012). It was demonstrated that only the
plasma membrane-associated F1Fo-ATPase, but not the mitochondria-
associated F1Fo-ATPase, was required for the release of inﬂuenza
viruses (Gorai et al., 2012). We therefore isolated themitochondria and
found that NS2-50HA did not locate in the mitochondria while F1β can
be detected in both the mitochondria and in the other cellular
components (Fig. S1). The data indicate that plasma membrane-
associated but not the mitochondria-associated F1Fo-ATPase plays
the role in affecting NS2 activity because the latter one has little
chance to get access to NS2.
In conclusion, we developed a Vero-adapted PR8 vaccine strain by
introducing the NS2K86R mutation. This mutation promotes the viral
assembly/budding process, which may relate to an enhanced interac-
tion between viral NS2 and subunits of host F1Fo-ATPase, F1β and FoB.
The mutation does not change the stability, antigenicity or pathogeni-
city of the PR8 vaccine strain, and this modiﬁed PR8 virus has the
potential to become a vaccine seed virus.
Materials and methods
Plasmids
Plasmids containing the eight segments of A/Puerto Rico/8/34
(H1N1) (pHW2000-HA, pHW2000-NA, pHW2000-M, pHW2000-
NP, pHW2000-PB1, pHW2000-PB2, pHW2000-PA, and pHW2000-
NS) were kindly provided by Prof. Robert G. Webster (St. Jude
Children's Research Hospital, University of Tennessee). Plasmids
containing the eight segments of A/WSN/33(H1N1) in pHW2000 were
kindly provided by Prof. Hans-Dieter Klenk (Philipps University of
Marburg, Germany). Mutations in the NS gene were introduced using
the QuikChange site-directed mutagenesis kit (Stratagene) with pri-
mers designed following the manufacturer's protocol. All resulting
plasmid sequences were conﬁrmed by commercial sequencing.
To generate plasmids for the expression of N-terminal HA-
tagged NS2, the ORF of NS2 was cloned into the expression plasmid
pCAGGS (kindly provided by Dr. Jun-ichi Miyazaki from Osaka
University, Japan) in-frame with an HA-tag sequence at the 50 end.
Viruses and cells
The African green monkey kidney cells (Vero), Madin–Darby
canine kidney cells (MDCK) and human embryonic kidney 293T
cells (293T) were purchased from the American Type Culture
Collection (ATCC) and maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM, Gibco) supplemented with 10% fetal bovine
serum (FBS) (HyClone) at 37 1C in 5% CO2.
The A/WSN/33 (H1N1) and A/PR/8/34 (H1N1) viruses were
rescued using plasmid-based reverse genetics, followed by two
rounds of plaque puriﬁcation and propagation in MDCK cells for
stock development. The PR8 virus was further propagated in SPF
chicken embryos. PR8–WSNM, PR8–WSN NS, PR8–WSN 4P and all
the PR8-based single-mutation viruses were also generated using
plasmid-based reverse genetics, followed by two rounds of plaque
puriﬁcation and propagation in MDCK cells for stock development.
Viral plaque assay and titration
The viral plaque assay with immunostaining was performed as
previously described (Matrosovich et al., 2006). Vero cells were
cultivated in 24-well plates in DMEM containing 10% FBS. For
infection, cells were washed with PBS, and the medium was
changed to DMEM containing 0.2% BSA and 1.0 μg/ml TPCK-
trypsin. The cells were infected with 10-fold serially diluted virus
preparations. After 1 h of incubation at 37 1C in 5% CO2, the
medium was removed, and 1 ml of 4% Avicel medium (2 DMEM
containing 0.4% BSA and 2.0 μg/ml TPCK-trypsin¼1:1; FMC Cor-
poration) was added. Cells were incubated for 48 h at 37 1C in 5%
CO2 and then ﬁxed with 4% PFA. Immunostaining was performed
using an anti-NP polyclonal antibody conjugated with HRP (Anti-
body Research Centre, Shanghai Institute of Biological Science).
True Blue substrate (KPL) was added to visualize the plaques. The
titration of viruses was performed in MDCK cells following the
above protocol.
Replication kinetics in Vero cells
Vero cell monolayers were infected with the indicated viruses
at an MOI of 0.001 and then incubated for 1 h at 37 1C in 5% CO2
before the infection culture was replaced with fresh DMEM
containing 0.2% BSA and 1.0 μg/ml TPCK-trypsin. The supernatants
were collected at the indicated time points post-infection and
stored at 80 1C until the titration of each virus sample was
determined by plaque assay in MDCK cells. Vero cell monolayers
were infected with viruses at an MOI of 1 during the single-step
growth curve.
Luciferase reporter assay
Vero cells cultured in 24-well plates were transiently trans-
fected with a plasmid mixture containing inﬂuenza A virus PB1-,
PB2-, PA-, and NP-expression plasmids (100 ng each) as well as
pPolI-HA-Luc (100 ng; kindly provided by Prof. Georg Kochs,
Freiburg University, Germany) and pRL-SV40 (10 ng; Promega),
using the X-treme GENE HP DNA Transfection Reagent (Roche)
according to the manufacturer's instructions. The pPolI-HA-Luc is a
human polymerase I (Pol I) expression plasmid expressing lucifer-
ase gene ﬂanked by noncoding sequences of segment 4 (HA) of
FluA, thus the viral polymerase activity can be monitored by
detecting the activity of reporter protein ﬁreﬂy luciferase. The
vector or NS2-expressing plasmids were also co-transfected. Cells
were harvested 24 h after transfection, and the luciferase assay
was performed using the Dual-Luciferase reporter assay system
(Promega) according to the manufacturer's protocol. All experi-
ments were performed in triplicate.
To examine the polymerase activity in infected cells, pPolI-HA-
Luc (100 ng) and pRL-SV40 (10 ng) were transfected into Vero cells.
Cells were infected with a high MOI of 5 at 24 h post-transfection
and harvested at the indicated time points post-infection. The
luciferase assay was performed as described above.
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The cell lysis collected in the luciferase assay was further
subjected to Western Blot analysis. The expression of NP and NS2-
HA was detected by using mouse anti-NP (kindly provided by Prof.
Ningshao Xia, Xiamen University, China) and mouse anti-HA anti-
bodies (Antibody Research Centre, Shanghai Institute of Biolo-
gical Science). In infected cells, the expressions of viral NP and
NS1 were detected by using mouse anti-NP and rabbit anti-NS1
(Antibody Research Centre, Shanghai Institute of Biological Science).
Strand-speciﬁc real-time RT-PCR
Vero cells cultured in 12-well plates were incubated with
viruses at an MOI of 1 for 1 h at 37 1C in 5% CO2 before the
infection medium was replaced with fresh DMEM containing 0.2%
BSA and 1.0 μg/ml TPCK-trypsin. Cells were harvested at the
indicated time points, and the total cellular RNA was extracted
using the TRIzol RNA isolation reagent (Invitrogen). For each
sample, 0.5 μg of RNA was reverse transcribed using strand-
speciﬁc tagged primers (Kawakami et al., 2011) for the PR8 virus
using the ReverTra Ace qPCR RT Kit (Toyobo) according to the
manufacturer's instructions. Real-time quantitative PCR (qPCR)
was performed with the SYBR Green Real-time PCR Master Mix
(Toyobo) according to the manufacturer's instructions on an ABI
PRISM 7900HT instrument. The cycling conditions for qPCR were
95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C
for 1 min.
Cell fractionation
To determine the localization of the viral NP protein during the
viral infection process, Vero cells were infected with viruses at an
MOI of 1. At the indicated time points, the cells were washed with
cold PBS before being scraped off and suspended in PBS. Cell
pellets were collected by centrifugation at 10,000 g for 5 min
and re-suspended by pipetting up and down several times in
sucrose buffer (10 mM HEPES at pH 7.9, 0.34 M sucrose, 3 mM
CaCl2, 2 mM Mg-acetate, and 0.11 mM EDTA) with 0.5% NP-40 and
complete protease inhibitors (Roche). The suspension was incu-
bated on ice for 10 min and centrifuged at 12,000 g for 5 min.
The resulting supernatant was collected as the cytoplasmic frac-
tion. The remaining pellet was washed with sucrose buffer and
collected as the nuclear fraction by centrifugation at 12,000 g for
5 min.
Immunoprecipitation and western blotting
Vero cells were transfected with the indicated HA-tagged NS2
plasmids using the X-treme GENE HP DNA Transfection Reagent
(Roche). After 48 h, the cells were incubated with lysis buffer
(50 mM Tris HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, and 1%
NP-40) containing complete protease inhibitors (Roche) for 1 h at
4 1C. After centrifugation to remove cellular debris, the super-
natants were incubated with anti-HA agarose (Sigma) overnight at
4 1C. Subsequently, the beads were washed 5 times with lysis
buffer and eluted with SDS loading buffer, and eluates were
separated by SDS-PAGE. The proteins were transferred to nitro-
cellulose membranes (Bio-Rad), and the NS2 proteins were
detected with anti-HA polyclonal primary antibodies (Sigma) and
horseradish-peroxidase-(HRP)-conjugated goat anti-rabbit IgG
secondary antibodies (Southern Biotech). The endogenous F1β
proteins were detected with rabbit anti-ATP5B (Sigma) and HRP-
conjugated goat anti-rabbit IgG secondary antibodies (Southern
Biotech). The endogenous FoB proteins were detected with goat
anti-ATP5F1 (Santa Cruz) and HRP-conjugated donkey anti-goat
IgG secondary antibodies (Santa Cruz).
Mitochondria isolation
Mitochondria were isolated from 6 cm-dish Vero cells by using
the Mitochondria Isolation Kit for Cultured Cells (Thermo) and all
the operations followed the instructions. Except for the mitochon-
dria isolations, all the other components were mixed together for
SDS/PAGE. VDAC1 acts as the biomarker of mitochondria and
was detected with rabbit anti-VDAC1 (Cell Signaling) and HRP-
conjugated goat anti-rabbit IgG secondary antibodies (Southern
Biotech).
Chicken embryo lethality test
Ten-day-old embryonated chicken eggs were inoculated in the
allantoic cavity with 10-fold dilutions of the indicated viruses
(106–102 PFU/egg) in a 100-μl volume. The embryo viability was
recorded at 48 h post-inoculation. The ELD50 of the viruses was
calculated using the Reed and Muench method.
Infection of mice
To evaluate the virulence in mice, the MLD50 of each indicated
virus was determined as previously described (Gao et al., 1999).
Brieﬂy, groups (n¼5) of 6- to 8-week-old female BALB/c mice were
anesthetized with diethylether and intranasally infected with
serial 10-fold dilutions of the indicated viruses (104–101 PFU/
mouse) in a 50-μl volume. Body weight was recorded daily for
14 days. All mice that lost 425% of their initial body weight were
euthanized according to the Institutional Animal Care and Use
Committee guidelines. The MLD50 for the viruses was calculated
according to the Reed and Muench method.
Antibodies
The mouse anti-HA-tag (Covance), mouse anti-GAPDH (Abmart),
rabbit anti-HA-tag (Sigma), mouse anti-actin (AOGMA), rabbit anti-
histone3 (Cell Signaling), and rabbit anti-F1β (ATP5B) (Sigma) were
purchased from the indicated commercial sources. Rabbit anti-M1,
rabbit anti-NP-HRP and rabbit anti-NS1 were obtained from the
Antibody Research Centre, Shanghai Institute of Biological Science.
The following secondary antibodies were used: HRP-conjugated
anti-mouse IgG antibody and HRP-conjugated anti-rabbit IgG anti-
body (Southern Biotech).
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